Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Do direct acting antivirals cure chronic hepatitis C?

We were dismayed that the Editors of the BMJ presented the widely discredited Cochrane review of Hepatitis C virus therapy as mainstream opinion. It is not... There is no credible explanation for the fall in hepatitis C liver disease morbidity and mortality associated with the introduction of effective anti-virals other than the use of these drugs.

Published
18 May 2018
From
BMJ
Do fatigue and quality of life improve after hepatitis C is cured?

Patient-reported outcomes such as fatigue, vitality and mental health improve substantially in the two years following hepatitis C cure for people with cirrhosis, but people

Published
16 May 2018
By
Keith Alcorn
How states could be saving more hepatitis C patients

USC’s Neeraj Sood and colleagues propose an approach that leverages competition among drug manufacturers, saving states money and ensuring that more people get treatment

Published
15 May 2018
From
USC News
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents

Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need.

Published
14 May 2018
From
Intellectual Property Watch
Gilead Topples As Its Hepatitis C Drug Franchise Continues To Crumble

Sales of hepatitis C drugs Harvoni, Sovaldi and Epclusa raked in $1.05 billion, declining 59%. That was the single biggest year-over-year decline in the eight quarters since Gilead started reporting sales of hepatitis C drugs separately from its other antiviral products.

Published
02 May 2018
From
Investor's Business Daily
Many European countries are not ready to stop viral hepatitis

Many European countries lack a comprehensive policy to eliminate viral hepatitis as a major public health threat, according to a patient group-based survey implemented in 25 countries. The Hep-CORE study was coordinated by ISGlobal - an institution supported by the "la Caixa" Foundation - and led by the European Liver Patient's Association.

Published
19 April 2018
From
Eurekalert Medicine & Health
Routine clinical use of DAAs highly effective and safe in people with HIV/HCV in Europe

“Real life” data from across Europe shows that direct-acting antivirals (DAAs) cure hepatitis C in the vast majority of people with HIV and hepatitis C

Published
19 April 2018
By
Michael Carter
Curing hepatitis C reduces deaths and liver disease

Curing hepatitis C infection significantly reduces deaths from liver disease and reduces the incidence of decompensation, two large prospective studies from Italy and Scotland show.

Published
18 April 2018
By
Keith Alcorn
Direct-acting antivirals bring fewer HCV-related liver transplants, better survival after transplantation, in Europe

There has been a steep fall in the number of hepatitis C virus (HCV)-related liver transplants since the introduction of direct-acting antivirals (DAAs), according to

Published
16 April 2018
By
Michael Carter
Eight weeks of treatment with Epclusa cured almost all people with HCV receiving opioid substitution therapy

An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons

Published
13 April 2018
By
Keith Alcorn
← First12345...99Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.